Index RUT
P/E 12.42
EPS (ttm) 2.45
Insider Own 5.65%
Shs Outstand 57.71M
Perf Week -1.07%
Market Cap 1.78B
Forward P/E -
EPS next Y -1.11
Insider Trans -5.02%
Shs Float 55.34M
Perf Month 23.32%
Income 162.11M
PEG -
EPS next Q -0.60
Inst Own 99.83%
Short Float 6.28%
Perf Quarter 2.98%
Sales 314.95M
P/S 5.66
EPS this Y 198.08%
Inst Trans -9.30%
Short Ratio 6.21
Perf Half Y 80.69%
Book/sh 9.56
P/B 3.18
EPS next Y -181.12%
ROA 37.30%
Short Interest 3.47M
Perf Year 21.06%
Cash/sh 5.50
P/C 5.53
EPS next 5Y -
ROE 41.75%
52W Range 13.72 - 33.34
Perf YTD 32.62%
Dividend Est. -
P/FCF -
EPS past 5Y 4.38%
ROI 28.93%
52W High -8.79%
Beta 2.13
Dividend TTM -
Quick Ratio 15.72
Sales past 5Y 2462.45%
Gross Margin 98.95%
52W Low 121.65%
ATR (14) 1.25
Dividend Ex-Date -
Current Ratio 15.72
EPS Y/Y TTM 191.97%
Oper. Margin 47.21%
RSI (14) 59.39
Volatility 3.93% 4.35%
Employees 112
Debt/Eq 0.00
Sales Y/Y TTM 36565.08%
Profit Margin 51.47%
Recom 1.17
Target Price 43.50
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 588.87%
Payout -
Rel Volume 0.64
Prev Close 30.54
Sales Surprise -2.88%
EPS Surprise -3.17%
Sales Q/Q -
Earnings May 08 AMC
Avg Volume 559.75K
Price 30.41
SMA20 7.31%
SMA50 9.18%
SMA200 34.19%
Trades
Volume 355,498
Change -0.43%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-30-23 Initiated
CapitalOne
Overweight
$32
May-25-23 Resumed
Jefferies
Buy
$30 → $40
Aug-25-22 Initiated
JMP Securities
Mkt Outperform
$21
Feb-11-22 Initiated
BTIG Research
Buy
$55
Oct-12-21 Upgrade
JP Morgan
Neutral → Overweight
$49 → $55
Oct-11-21 Upgrade
Northland Capital
Market Perform → Outperform
$40
Sep-20-21 Downgrade
JP Morgan
Overweight → Neutral
$60 → $49
May-24-21 Initiated
Northland Capital
Outperform
$42
May-24-21 Initiated
JMP Securities
Mkt Outperform
$48
Jan-06-21 Initiated
JP Morgan
Overweight
Dec-16-20 Initiated
Piper Sandler
Overweight
$53
Sep-18-20 Reiterated
H.C. Wainwright
Buy
$28 → $33
Jul-15-20 Initiated
Jefferies
Buy
$27
May-18-20 Reiterated
H.C. Wainwright
Buy
$23 → $28
Jul-08-19 Initiated
H.C. Wainwright
Buy
$23
May-09-19 Upgrade
Stifel
Hold → Buy
$11 → $17
Dec-06-18 Initiated
Nomura
Buy
$13
Jan-29-18 Initiated
Stifel
Buy
$32
Jul-21-17 Initiated
BTIG Research
Buy
$36
Show Previous Ratings
May-14-24 04:05PM
May-07-24 11:53PM
09:04PM
04:23PM
(Associated Press Finance)
04:10PM
04:05PM
Loading…
04:05PM
Apr-16-24 09:00AM
Apr-05-24 12:00PM
Apr-03-24 01:52AM
Mar-26-24 07:00AM
Mar-18-24 09:55AM
07:00AM
Mar-11-24 07:00AM
Mar-06-24 04:05PM
Mar-01-24 12:20PM
12:00PM
Loading…
12:00PM
12:00PM
09:55AM
08:50AM
Feb-27-24 04:38PM
(Associated Press Finance)
04:05PM
Feb-21-24 05:00PM
Feb-20-24 04:05PM
Feb-15-24 03:13AM
Feb-07-24 05:00PM
Feb-02-24 01:03PM
Feb-01-24 06:35AM
Jan-31-24 04:05PM
Jan-29-24 07:30AM
Jan-12-24 03:02AM
07:30AM
Loading…
Jan-03-24 07:30AM
Dec-16-23 11:01AM
Dec-13-23 07:30AM
Dec-12-23 09:04AM
Nov-27-23 09:00AM
Nov-16-23 04:05PM
05:50AM
Nov-09-23 03:55PM
09:55AM
Nov-04-23 05:42AM
Nov-02-23 06:24PM
(Associated Press Finance)
04:05PM
09:05AM
Nov-01-23 04:05PM
07:30AM
Oct-30-23 04:05PM
Oct-09-23 07:00AM
Oct-03-23 04:05PM
Sep-05-23 07:30AM
Aug-16-23 04:05PM
Aug-09-23 07:00AM
Aug-03-23 04:48PM
(Associated Press Finance)
04:05PM
Jul-18-23 04:05PM
Jul-05-23 09:33AM
Jul-04-23 03:30AM
Jun-30-23 08:50AM
Jun-15-23 09:55AM
Jun-13-23 08:50AM
Jun-09-23 08:05AM
Jun-06-23 07:30AM
Jun-01-23 04:01PM
May-26-23 09:55AM
May-12-23 03:14PM
07:00AM
May-11-23 04:05PM
10:17AM
May-05-23 04:03PM
(Investor's Business Daily) +5.13%
May-04-23 05:02PM
04:05PM
Apr-20-23 09:51PM
Apr-17-23 06:35AM
(Simply Wall St.) +10.03%
Apr-04-23 10:45PM
04:11PM
Mar-21-23 03:49AM
Mar-20-23 06:08AM
Mar-17-23 06:06AM
Mar-15-23 04:01PM
01:39PM
07:30AM
Mar-09-23 11:14AM
Mar-08-23 12:19PM
10:02AM
Mar-07-23 11:54AM
08:00AM
Jan-25-23 03:24AM
Jan-14-23 07:14AM
Dec-21-22 04:05PM
Dec-05-22 09:55AM
Dec-01-22 07:05AM
Nov-16-22 04:05PM
Nov-11-22 09:55AM
05:11AM
Nov-08-22 04:05PM
Nov-03-22 09:16AM
Oct-12-22 06:10AM
Oct-05-22 09:55AM
Oct-02-22 07:39AM
Sep-23-22 12:00PM
Sep-20-22 05:40PM
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ali Asif Chief Financial Officer Apr 18 '24 Sale 25.11 1,234 30,986 37,163 Apr 19 08:05 PM PATEL DINESH V PH D President and CEO Apr 01 '24 Sale 28.31 25,000 707,750 549,590 Apr 02 08:29 PM SELICK HAROLD E Director Mar 07 '24 Option Exercise 1.89 6,490 12,266 27,996 Mar 11 08:00 PM Ali Asif Chief Financial Officer Mar 01 '24 Option Exercise 12.17 12,000 146,040 52,645 Mar 01 08:45 PM Waddill William D. Director Mar 01 '24 Option Exercise 6.09 12,975 79,018 24,975 Mar 01 08:45 PM PATEL DINESH V PH D President and CEO Mar 01 '24 Sale 31.62 30,000 948,600 574,590 Mar 01 08:46 PM Ali Asif Chief Financial Officer Mar 01 '24 Sale 32.24 14,248 459,318 38,397 Mar 01 08:45 PM Waddill William D. Director Mar 01 '24 Sale 31.34 12,975 406,636 12,000 Mar 01 08:45 PM Ali Asif Chief Financial Officer Feb 29 '24 Sale 30.69 9,939 305,048 40,645 Mar 01 08:45 PM Gupta Suneel Chief Development Officer Jan 09 '24 Option Exercise 7.38 5,000 36,900 192,567 Jan 11 08:00 PM Gupta Suneel Chief Development Officer Jan 09 '24 Sale 25.00 5,000 125,000 187,567 Jan 11 08:00 PM PATEL DINESH V PH D President and CEO Dec 13 '23 Sale 20.08 75,000 1,506,000 534,347 Dec 15 04:30 PM MOLINA ARTURO MD Chief Medical Officer Nov 15 '23 Sale 16.24 1,848 30,012 22,527 Jan 04 08:09 PM Gupta Suneel Chief Development Officer Oct 19 '23 Option Exercise 7.38 20,000 147,600 168,317 Oct 23 04:31 PM PATEL DINESH V PH D President and CEO Oct 18 '23 Option Exercise 4.21 6,000 25,260 609,347 Oct 19 04:55 PM
Index RUT
P/E -
EPS (ttm) -4.24
Insider Own 5.28%
Shs Outstand 124.20M
Perf Week 0.44%
Market Cap 3.09B
Forward P/E -
EPS next Y -2.71
Insider Trans -3.57%
Shs Float 117.64M
Perf Month 13.76%
Income -470.79M
PEG -
EPS next Q -0.52
Inst Own 77.22%
Short Float 7.94%
Perf Quarter -18.40%
Sales 35.47M
P/S 87.12
EPS this Y -59.65%
Inst Trans -1.58%
Short Ratio 7.90
Perf Half Y -14.09%
Book/sh 3.90
P/B 6.38
EPS next Y 11.53%
ROA -50.99%
Short Interest 9.34M
Perf Year -30.05%
Cash/sh 4.21
P/C 5.91
EPS next 5Y 7.33%
ROE -101.18%
52W Range 20.67 - 39.83
Perf YTD -18.69%
Dividend Est. -
P/FCF -
EPS past 5Y -24.19%
ROI -53.60%
52W High -37.53%
Beta 0.96
Dividend TTM -
Quick Ratio 8.31
Sales past 5Y 205.96%
Gross Margin 55.12%
52W Low 20.37%
ATR (14) 1.21
Dividend Ex-Date -
Current Ratio 8.31
EPS Y/Y TTM -197.97%
Oper. Margin -1335.58%
RSI (14) 52.09
Volatility 3.36% 5.02%
Employees 525
Debt/Eq 0.83
Sales Y/Y TTM -87.00%
Profit Margin -1327.18%
Recom 1.57
Target Price 52.38
Option/Short Yes / Yes
LT Debt/Eq 0.82
EPS Q/Q -325.79%
Payout -
Rel Volume 0.47
Prev Close 24.67
Sales Surprise -100.00%
EPS Surprise -116.15%
Sales Q/Q -100.00%
Earnings May 09 AMC
Avg Volume 1.18M
Price 24.88
SMA20 3.40%
SMA50 -1.11%
SMA200 -11.45%
Trades
Volume 561,953
Change 0.85%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-04-23 Initiated
BofA Securities
Buy
$29
Sep-19-23 Initiated
Citigroup
Neutral
$33
Jul-21-23 Initiated
TD Cowen
Outperform
May-12-23 Downgrade
SVB Securities
Outperform → Market Perform
$40
Apr-26-23 Initiated
SMBC Nikko
Outperform
$80
Apr-12-23 Upgrade
SVB Securities
Market Perform → Outperform
$21 → $35
Mar-21-23 Initiated
Bernstein
Mkt Perform
$27
Sep-09-22 Initiated
Morgan Stanley
Equal-Weight
$41
May-11-22 Upgrade
Robert W. Baird
Neutral → Outperform
$71 → $60
Jan-19-22 Resumed
Goldman
Buy
$90 → $85
Aug-06-21 Reiterated
Chardan Capital Markets
Buy
$97 → $94
Jun-04-21 Resumed
Robert W. Baird
Neutral
$85
Feb-05-21 Reiterated
H.C. Wainwright
Buy
$90 → $95
Dec-21-20 Downgrade
Robert W. Baird
Outperform → Neutral
$75
Dec-16-20 Initiated
UBS
Buy
$95
Nov-19-20 Initiated
Citigroup
Buy
$90
May-13-20 Initiated
RBC Capital Mkts
Outperform
$62
May-08-20 Upgrade
Oppenheimer
Perform → Outperform
$58
Apr-15-20 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$55 → $60
Mar-24-20 Upgrade
SVB Leerink
Underperform → Mkt Perform
$29
Show Previous Ratings
May-20-24 11:04AM
06:00AM
May-14-24 07:08AM
May-10-24 01:03PM
12:26PM
11:32AM
Loading…
11:32AM
May-09-24 11:54PM
04:34PM
04:14PM
(Associated Press Finance)
04:01PM
May-03-24 07:26AM
May-02-24 04:01PM
Apr-29-24 07:30AM
Apr-26-24 07:30AM
Apr-24-24 04:01PM
07:30AM
Loading…
07:30AM
Apr-16-24 09:00AM
Apr-07-24 09:00AM
Apr-04-24 01:27AM
Apr-01-24 04:30PM
Mar-25-24 08:00AM
Mar-11-24 06:53PM
Mar-08-24 11:29PM
07:30AM
Mar-04-24 07:30AM
Feb-07-24 10:42AM
10:02AM
(Thomson Reuters StreetEvents)
Feb-06-24 04:32PM
(Associated Press Finance)
04:32PM
04:01PM
04:01PM
Loading…
Jan-22-24 04:01PM
Jan-18-24 05:37AM
Jan-09-24 03:02AM
Jan-06-24 01:01PM
Jan-05-24 05:00PM
11:02AM
Jan-03-24 07:00AM
Dec-29-23 04:01PM
Dec-24-23 09:01AM
Dec-21-23 07:30AM
Dec-20-23 07:30AM
Dec-01-23 09:32AM
Nov-30-23 12:22PM
(Thomson Reuters StreetEvents) -26.85%
Nov-29-23 04:51PM
04:01PM
Nov-28-23 07:30AM
Nov-22-23 09:46PM
Nov-21-23 04:01PM
Nov-16-23 07:30AM
Nov-13-23 09:30AM
Nov-06-23 07:30AM
Nov-02-23 07:30AM
Oct-31-23 08:30AM
07:46AM
Oct-28-23 05:02AM
Oct-03-23 04:01PM
Sep-27-23 04:30PM
Sep-21-23 05:01AM
Sep-11-23 07:30AM
Sep-09-23 03:59PM
Sep-07-23 07:34PM
Sep-01-23 07:30AM
Aug-13-23 08:32AM
Aug-10-23 08:10AM
Aug-08-23 09:42AM
09:13AM
(Thomson Reuters StreetEvents)
06:20AM
Aug-07-23 04:16PM
04:01PM
Jul-24-23 04:00PM
Jul-17-23 07:30AM
Jul-06-23 04:30PM
Jun-30-23 06:52AM
Jun-27-23 07:30AM
Jun-24-23 08:15AM
Jun-21-23 08:00PM
Jun-14-23 06:34PM
Jun-06-23 07:30AM
Jun-01-23 04:07PM
(Investor's Business Daily)
07:30AM
07:07AM
May-23-23 07:30AM
May-16-23 07:30AM
May-15-23 04:00PM
May-11-23 09:27AM
(Zacks Small Cap Research)
May-10-23 06:25AM
May-04-23 06:24AM
May-02-23 04:17PM
04:01PM
Apr-26-23 08:00PM
07:06AM
Apr-25-23 01:19PM
11:20AM
07:30AM
Apr-18-23 07:30AM
Apr-17-23 08:17AM
Apr-16-23 05:21AM
Apr-12-23 07:30AM
Apr-04-23 04:30PM
07:30AM
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vakiener Victoria Director May 02 '24 Sale 23.31 1,799 41,935 30,205 May 06 06:04 PM Hamilton James C Chief Discovery/Trans Medicine Apr 01 '24 Sale 28.03 6,000 168,180 204,851 Apr 03 06:05 PM Lu Hongbo Director Mar 20 '24 Buy 27.50 1,000 27,500 33,680 Mar 20 07:06 PM Lu Hongbo Director Mar 19 '24 Buy 28.00 1,000 28,000 32,680 Mar 20 07:06 PM Lu Hongbo Director Mar 18 '24 Buy 27.49 1,000 27,490 31,680 Mar 20 07:06 PM Myszkowski Kenneth Allen Chief Financial Officer Mar 06 '24 Sale 35.19 40,000 1,407,600 400,600 Mar 08 05:54 PM Anzalone Christopher Richard Chief Executive Officer Jan 31 '24 Option Exercise 14.54 57,499 836,035 3,772,547 Feb 02 05:25 PM Anzalone Christopher Richard Chief Executive Officer Jan 31 '24 Sale 32.35 57,499 1,860,019 3,715,048 Feb 02 05:25 PM Hamilton James C Chief Discovery/Trans Medicine Jan 12 '24 Sale 36.89 7,940 292,904 210,851 Jan 17 06:32 PM Vakiener Victoria Director Jan 11 '24 Sale 38.10 4,720 179,813 32,001 Jan 16 06:06 PM Waddill William D. Director Jan 11 '24 Sale 38.07 3,934 149,759 47,870 Jan 16 06:06 PM Ferrari Mauro Director Jan 11 '24 Sale 38.06 3,147 119,787 60,778 Jan 16 06:06 PM GIVEN DOUGLAS B Director Jan 11 '24 Sale 38.06 2,911 110,788 129,711 Jan 16 06:06 PM Hamilton James C Chief Discovery/Trans Medicine Jan 05 '24 Sale 35.18 32,143 1,130,748 218,791 Jan 05 08:02 PM O'Brien Patrick COO and General Counsel Jan 05 '24 Sale 35.27 22,841 805,716 464,385 Jan 05 07:58 PM Myszkowski Kenneth Allen Chief Financial Officer Jan 05 '24 Sale 35.27 16,104 567,910 440,600 Jan 08 05:16 PM San Martin Javier Chief Medical Officer Jan 05 '24 Sale 35.26 8,303 292,804 198,497 Jan 08 05:16 PM Oliver Tracie Chief Commercial Officer Jan 05 '24 Sale 33.89 74 2,508 136,501 Jan 08 05:17 PM O'Brien Patrick COO and General Counsel Jan 04 '24 Sale 32.63 1,600 52,208 402,226 Jan 05 07:58 PM O'Brien Patrick COO and General Counsel Jan 03 '24 Sale 32.28 8,749 282,439 403,826 Jan 05 07:58 PM Hamilton James C Chief Discovery/Trans Medicine Jan 03 '24 Sale 32.19 6,300 202,781 175,934 Jan 05 08:02 PM Anzalone Christopher Richard Chief Executive Officer Jan 02 '24 Sale 31.01 9,952 308,637 3,715,048 Jan 04 05:25 PM Anzalone Christopher Richard Chief Executive Officer Dec 20 '23 Sale 28.54 12,000 342,480 3,725,000 Dec 22 05:04 PM San Martin Javier Chief Medical Officer Nov 20 '23 Sale 28.80 19,700 567,315 131,800 Nov 22 02:31 PM Anzalone Christopher Richard Chief Executive Officer Oct 25 '23 Sale 24.21 24,338 589,223 3,737,000 Oct 27 06:23 PM Vakiener Victoria Director Sep 28 '23 Sale 26.33 1,550 40,812 21,734 Oct 02 05:51 PM Anzalone Christopher Richard Chief Executive Officer Sep 18 '23 Option Exercise 4.75 57,755 274,336 3,819,093 Sep 20 06:10 PM Anzalone Christopher Richard Chief Executive Officer Sep 18 '23 Sale 28.12 57,755 1,624,223 3,761,338 Sep 20 06:10 PM Oliver Tracie Chief Commercial Officer Jul 03 '23 Sale 35.31 8,925 315,142 61,575 Jul 06 06:04 PM Hamilton James C Chief Discovery/Trans Medicine Jun 30 '23 Sale 35.53 3,000 106,590 188,484 Jul 05 06:15 PM Myszkowski Kenneth Allen Chief Financial Officer Jun 27 '23 Sale 36.20 15,000 543,000 381,704 Jun 29 06:41 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite